Abstract:
Influenza virus infection poses a serious threat to human health, and vaccination remains one of the most effective measures for influenza prevention and control. Live attenuated influenza vaccine (LAIV), administered intranasally to mimic natural infection, can simultaneously induce humoral, cellular, and respiratory mucosal immunity, and represents an important technological platform for the development of broad-spectrum influenza vaccines. In recent years, with advances in reverse genetics, synthetic biology, and genetic engineering, LAIV development has gradually shifted from traditional empirical attenuation toward rational design based on viral pathogenic mechanisms and host-virus interactions. This review systematically summarizes the major rational design strategies for influenza A LAIVs in recent years, analyzes their attenuation mechanisms, viral replication characteristics, safety and immune-protection profiles, and discusses the challenges and prospects of their clinical translation, to provide a reference for optimizing future attenuation strategies and for the development and clinical translation of novel LAIVs. Overall, rational design provides a new technological pathway for developing safer, more effective, broad-spectrum, and rapid-response LAIVs and is expected to be an important direction for advancing innovative research and development of influenza vaccines.